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C ongenital heart defects (CHDs) are the most commontype of birth defect occurring in 1% of live births1 and,
if minor cardiac abnormalities such as bicuspid aortic valve
are included, then the prevalence may be as high as 2% to
3%.2 Advances in surgical and perioperative care and
catheter-based interventions have dramatically improved
survival, yet there continues to be 20% early mortality for
the most complex cardiac defects.3 Furthermore, many of the
survivors need long-term medical care and have functional
deficits in cognition, behavior, attention, and exercise perfor-
mance that limit educational and employment opportunities
and reduce their quality of life.4 As survival for patients with
CHD has improved, there has been an increased emphasis on
understanding variation in outcome and in improving short-
and long-term outcomes, which include but are not limited to
survival. While recent efforts to optimize and standardize
clinical practice and perioperative care have resulted in small
incremental improvements, they have not led to major
advances in clinical outcomes. Increasingly, the focus of
outcomes research is on understanding the differences
between individual patients (including genetic factors and
specific variations in clinical care or clinical course) that
predict or determine clinical outcomes.
Recently, the effort to better understand and improve
clinical outcomes has been aided by complementary
initiatives to identify the causes of CHD. A fall in the costs
of high-throughput DNA sequencing, advances in bioinfor-
matic analyses, and an investment in funding the collection
and genetic characterization of large cohorts of patients with
CHD has rapidly advanced our understanding of the genetic
architecture of CHD. What is emerging is an improved
understanding of how underlying genetic factors can influence
specific measured clinical outcomes and the importance of
considering these factors when assessing the effectiveness of
interventions and new treatment approaches. In this review,
we will examine clinical outcomes such as survival, cognition
and behavior, growth, and cardiac function for patients with
CHD in the context of specific genetic etiologies.




Even with the improvement in postoperative survival for most
types of CHD, survival rates remain an important clinical
outcome for complex CHD for which early mortality can be as
high as 20% and late mortality is a relatively common
occurrence.3 Further improvements in survival will require a
better understanding of patient-specific risk factors that
confer a higher risk for an adverse clinical outcome during the
longitudinal management of CHD. Individual risk factors will
also need to be categorized with respect to the timing of their
impact on survival. Different mechanisms likely drive early,
sometimes referred to as surgical or procedural mortality as
opposed to late events. As more individuals with CHD survive
into adulthood, the importance of understanding determinants
of longitudinal survival increases. Clearly, genetic factors are
an important contributor to differences between patients and,
not surprisingly, genetic syndromes and nonsyndromic
genetic variation have been noted to have a significant effect
on long-term survival after repair or palliation of CHD. Since
cardiac transplantation is often used to rescue a patient who
has failed surgical and medical management of their cardiac
defect, patients who have required cardiac transplantation are
often grouped with nonsurvivors to denote treatment failures.
Since death and heart transplant are relatively infrequent
occurrences, these outcomes will occasionally be grouped
with major adverse events such as cardiac arrest, need for
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extracorporeal support, renal failure requiring dialysis, and
other life-threatening complications to yield an “event-free” or
“complication-free” survival.
Growth
Growth failure in CHD is a major and potentially modifiable
comorbidity.5 In single-ventricle populations, poor somatic
growth is associated with prolonged hospitalization,
decreased transplant-free survival, and increased neurodevel-
opmental disabilities.5–10 Poor somatic growth for a child with
CHD begins in utero. The cause of poor fetal growth is likely
multifactorial, involving genetic and placental risk factors
along with abnormal regional blood flow and oxygenation.11–15
With an increased focus on somatic growth, nutritional
interventions have become emphasized across many centers,
including being a major focus of the National Pediatric
Cardiology Quality Improvement Collaborative.16 Catch-up
weight gain is more achievable than attainment of normal
length (or height).17–19 Lack of improvement in linear growth as
well as the association between linear growth and neurodevel-
opmental outcomes9,10 raises suspicion that a large portion of
the variance in linear growth outcomes is driven by genetic
predisposition, a suspicion supported by the association of
pathogenic copy number variants (CNVs), linear growth, and
poor neurocognitive outcomes.20
Neurodevelopmental Performance
As long-term survival of CHD has dramatically improved, it is
becoming increasingly evident that CHD survivors often have
long-term disabilities, including permanent neurodevelopmen-
tal (ND) deficits that can affect school performance, employ-
ability, and quality of life. The majority of patients with the most
severe cardiac defects, such as complex single-ventricle
malformations, will have some degree of ND impairment and
15% to 30% will have severe cognitive and/or behavioral
deficits. The causes of ND impairment in CHD patients are
many and include developmental defects, abnormalities of the
maternal-fetal environment, and perioperative neurologic
injury (Figure 1). Despite the identification of many covariates,
combined, the known perioperative risk factors explain only
30% of the variance in ND outcomes, indicating that innate,
patient-specific genetic and physiologic factors may account
for much of the variance.21 Genetic factors strongly influence
brain development and contribute to the fetal response to the
in utero environment and perioperative injury processes. What
has made assessment of ND disabilities particularly challeng-
ing, in addition to the myriad of factors that can affect
neurodevelopment, is the broad range of ND domains that can
be affected and the fact that each of those domains and how
they are best measured changes with age. One of the earliest
measures that is commonly used is the Bayley Scales of Infant
Development (BSID), which has been updated twice, most
recently in 2006 (BSID-III).22 The most recent version allows
the assessment of ND performance in infancy across multiple
domains including cognition, language, motor skills, social-
emotional function, and adaptive behavior. This proctored test
can be supplemented with parent-reported outcomes assess-
ments such as the Ages and Stages Questionnaire (ASQ),23
which are well suited to ND follow-up programs since they do















Figure 1. Factors affecting neurodevelopmental outcomes. Measured neurodevelopmental outcomes are directly influenced by how the brain
has been formed and developed (brain development), whether or not it has been injured during development or perioperatively (brain injury), and
how it has been affected by the patient’s social and educational environment (social and educational factors). Genetic factors can have a primary
effect on brain development. They can also have a secondary or modifying effect (red arrows) on other factors that affect brain structure and
function, including hemodynamic factors, hypoxic/ischemic injury, and drug/toxin-mediated effects.
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As patients age, ND assessments can be expanded to
detect more subtle deficits in cognition and higher levels of
reasoning and processing and to better characterize attention
and behavior. Expanded ND assessments measure the
following domains: academic performance, IQ testing, lan-
guage skills, short-term memory, attention and executive
function, visual and spatial processing, fine motor skills, social
skills, adaptive skills, and emotional/behavioral function.
Previous studies have identified significant abnormalities in
each of these domains in patients with CHD, although there is
significant variability across patients and across CHD sub-
types. Perhaps most prevalent have been attention deficit/
hyperactivity disorders (ADHDs). A recent study evaluating
3552 CHD patients extracted from the National Health
Insurance Research Database in Taiwan revealed an adjusted
hazard ratio of 2.52 (95% confidence interval [CI], 1.96–3.2)
for being diagnosed with ADHD and an adjusted hazard ratio
of 1.97, (95% CI, 1.11–3.52) of being diagnosed with autism
spectrum disorder compared to age/sex-matched controls.24
The risks were even higher in subjects defined as having early
developmental disorders. The risk may also vary by CHD
subtype. A recent examination of 91 patients with tetralogy of
Fallot demonstrated an ADHD prevalence of 39% and 19% in
those with and without a genetic diagnosis, respectively,
compared with 5% of controls.25 Of 111 patients with single-
ventricle CHD, 66% of patients received a psychiatric
diagnosis, primarily anxiety disorder and ADHD, in long-term
follow-up compared with 22% of controls.26 Although many
studies looking at ND outcomes exclude individuals with
extracardiac anomalies, when included, studies have consis-
tently identified genetic factors as contributing to ND
outcomes in patients with CHD. Of 321 survivors of single
ventricle palliative repair who were evaluated at 14 months
of age, genetic syndromes/anomalies were an independent
risk factor for a lower-than-normative mental development
score (MDI) on the BSID-II assessment.27 In a study of 1770
subjects with a spectrum of CHD, the presence of genetic
syndrome and/or extracardiac anomaly was similarly associ-
ated with an increased risk of a lower MDI and PDI
(psychomotor developmental index) on the BSID-II adminis-
tered at 14 months of age.28 Taken together, these studies
support the importance of assessing ND performance in CHD
survivors and the significant impact that genetic factors have
on ND measures.
Ventricular Function
During operative repair or palliation of CHD, the heart is
usually arrested and emptied to yield a bloodless operative
field. The blood is circulated through a cardiopulmonary
bypass machine, where it is filtered, oxygenated, and returned
to the patient to perfuse all the organs and tissues including
the heart. For some CHD surgeries, a period of complete
circulatory arrest (no bypass flow) is required. Despite
refinement of the technical approaches and the limitation of
cardiopulmonary bypass and circulatory arrest times, injury to
multiple organs and tissues including the heart occurs. This
often results in a transient period of diminished ventricular
function that, when pronounced, is referred to as low cardiac
output syndrome.29 This diminished cardiac function can be
associated with an increased complication rate and decreased
event-free postoperative survival.30 Sustained and progressive
deficits in ventricular function can interfere with exercise
performance, affect quality of life, and ultimately lead to heart
failure, which may require heart transplantation. As with ND
performance, cardiac function can be impaired in patients
with CHD and can be caused by ischemia and ischemia-
reperfusion injury in the perioperative setting, mechanical
injury during surgery (eg, attributable to ventriculotomy), or
inherent genetically determined weaknesses and vulnerabili-
ties. Systolic and diastolic ventricular function can be serially
measured with echocardiographic or cardiac magnetic reso-
nance imaging. Better delineation of genetic factors affecting
ventricular function may aid the development of protective
strategies and promote improved risk stratification.
Genetic Architecture of CHD
Discussion of the impact of genetic factors on clinical
outcomes begins with an understanding of the genetic
architecture of CHD. Genetic contributors to CHD include
disorders of chromosome copy number (eg, Down syndrome),
subchromosomal deletions (eg, 22q11.2del) and duplications
(chromosome 1p21dup), rare monogenic pathogenic variants,
rare oligogenic deleterious variants, and common variants
(reviewed by Zaidi and Brueckner31). Identification of the
genetic causes of CHD has paralleled advances in genetic
technologies. Aneuploidies, detected by karyotyping, were the
first genetic variation associated with CHD. The trisomies (13,
18, and 21) and monosomies (Turner syndrome) along with
large subchromosomal deletions (22q11.2), detected by
fluorescent in situ hybridization and chromosomal microarray,
make up the genetic etiology of 9% to 18% of CHD.31 Single
gene etiologies, inherited in a Mendelian fashion, were initially
detected by linkage analysis of large pedigrees. These genes
were often transcription factors such as TBX5, GATA4, and
NKX2.5, mutations of which likely explain a small percentage
of CHD. Genome-wide and high-throughput sequencing tech-
nologies have enabled unbiased and thorough interrogation of
the exome, the protein coding portion of the genome. Exome
sequencing of probands and their unaffected parents have
determined that 10% of CHD is caused by de novo (ie, not
occurring in either parent) coding variants. If the CHD is
accompanied by extracardiac anomalies and/or ND
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abnormalities, then de novo variants may explain 20% of
disease.32 Pathogenic de novo variants typically occur in
genes that are highly expressed in the developing heart and
are enriched in certain biologic pathways such as chromatin
remodeling, ciliary function, notch signaling, and sarcomere
function. Single-nucleotide polymorphism microarrays and
novel analytic techniques of exome sequence data have
detected rare, pathogenic CNVs) in 10% of patients with
CHD.33,34
A large percentage of CHD remains unsolved (Figure 2: pie
chart of CHD causes).20,31–40 As larger numbers of exomes
are sequenced, it is becoming apparent that rare, inherited
variation plays a role, especially for isolated congenital heart
disease.35 Other genetic mechanisms (including somatic
mutation and multilocus variation) may have a role, as may
epigenetic changes, noncoding variation, and environmental
exposures.31
Each of these types of genetic variation can lead to
abnormalities of cardiac development, resulting in CHD. In
addition, concurrent developmental defects in other organs
and tissues and associated deficits in resiliency or resistance
to injury can lead to reduced survival and an increased rate of
complications and comorbidities. The same genetic variation,
therefore, can have pleiotropic effects and significantly impact
clinical outcomes beyond the development of the structural
heart disease. Progress in the understanding of the genetic
determinants of CHD and their impact on clinical outcomes
will be outlined in the subsequent sections.
Chromosomal Abnormalities and CNVs
Abnormal chromosomal copy number
Abnormalities of chromosomal copy number, including the
trisomies (13, 18, and 21) and monosomies (eg, Turner [45, X]
syndrome), are commonly associated with CHD, with an
incidence ranging from 80% to 90% for trisomy 13 and 18% to
50% for trisomy 21 (Down syndrome) and Turner syndrome.
Down syndrome (trisomy 21). CHD is common in patients
with Down syndrome, occurring in 40% to 50% of patients (see
Table 1).36 Early surgical studies reported worse surgical
outcomes in patients with Down syndrome undergoing repair
for complete atrioventricular septal defect compared with
patients without genetic syndromes.41,42 More recently,
several studies have demonstrated equal or decreased risk
of in-hospital mortality for patients with Down syndrome
undergoing repair of CHD (including complete atrioventricular
septal defect) compared with patients with normal karyotypes
Figure 2. Genetic determinants of congenital heart defects. The majority of congenital heart
defects do not have an identified genetic etiology. Unexplained CHD may be secondary to
noncoding genetic, epigenetic, and environmental factors, among others. All estimates are
approximate and are based on recent publications.20,31–40 CNVs indicates copy number variants.
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except among patients with single ventricle physiology.43–49
Several studies that included long-term outcomes for com-
plete atrioventricular septal defect repair have demonstrated
a decreased rate of reoperation for left atrioventricular valve
repair and for subaortic stenosis in patients with Down
syndrome, which is likely related to valve and left ventricular
outflow tract morphology differences.46,47,49
One group of patients with Down syndrome that does have
higher surgical risk is single-ventricle palliation. Subgroup
analysis demonstrated that among patients undergoing
staged single-ventricle palliation, patients with Down syn-
drome had higher in-hospital mortality rates.44 A study from
the Pediatric Cardiac Critical Care Consortium registry looking
at all patients undergoing Fontan palliation confirmed a
significantly increased mortality in patients with Down
syndrome compared with those without, with most of these
deaths occurring in the early postoperative period.50 This is
thought to be attributable to the increased risk of pulmonary
hypertension in these patients, which is not well tolerated in a
single-ventricle physiology.51
Although Down syndrome does not seem to confer an
increased risk ofmortality for most CHD repair, there have been
studies showing that there is increased morbidity including
significantly longer postoperative length of stay, increased risk
of respiratory52,53 and infectious complications,46,54 pulmonary
hypertension,44 higher rates of chylothorax,44 and increased
risk of postoperative complete heart block.44,46
Turner syndrome (45,X). Turner syndrome is a common
chromosomal condition caused by loss of part or all of the X
chromosome in females. Short stature is common, as are ND
deficits (see Table 1).55 Neurocognitive profiles in Turner
syndrome can include a decrement in IQ of 10 to 15 points,
learning disabilities, and challenges with executive function
and ADHD. Because many individuals with Turner syndrome
are mosaic, there is a wide range in severity of the associated
clinical features. As with Down syndrome, patients with
Turner syndrome have higher morbidity and mortality after
surgical palliation of single-ventricle heart disease compared
with patients without chromosomal abnormalities.56,57
Copy number variants
Copy number variants are large deletions or duplications of
DNA that usually involve at least 100 000 base pairs of DNA
but not the full chromosome. They can occur anywhere in the
genome but often occur at sites bounded by regions of repeat
or low-complexity sequence that allow mismatches during
DNA replication, resulting in duplication or loss of the
intervening DNA sequence. CNVs can either be inherited or
de novo. CNVs that are de novo, novel, oruncommon and are
large are more likely to be disease causing or pathogenic.
CNVs can involve one or more genes, and the resulting effects
on clinical phenotype and clinical outcomes can depend on
the number of genes involved and the roles of those genes in
development of the heart and other organs and tissues.
22q11.2 deletion syndrome. Recent population studies
indicate that the 22q11.2 deletion is the most common
microdeletion syndrome, occurring in 1 per 5950 live births37
and accounting for nearly 0.5% to 1.9% of all CHDs. Cardiac
defects occur in 60% to 75% of cases with 22q11.2
microdeletion,38,39 and there is an enhanced risk of CHD if
there is a concurrent partial microduplication of the histone
acetyltransferase complex member KANSL1 on chromosome
17q21.31,58 highlighting the effect of genetic modifiers on
clinical phenotype. The 22q11.2 deletion syndrome is
Table 1. Common Developmental Syndromes Associated With CHD
Condition/Diagnosis Genetic Defect Prevalence Cardiac Defect Associated Features
Down syndrome Trisomy 21 1 in 1000 births CAVSD, ASD, VSD,
PDA, TOF
Cardiac defects (40–50%); short stature; cognitive
deficits; atlantoaxial instability; immune system
dysfunction; hypotonia; hypothyroidism
Turner syndrome Monosomy X (may be
mosaic; may involve all or
part of X chromosome)
1 in 2000 to 5000
female births
CoA, BAV, Dilated Ao Cardiac defects (30%); short stature (partially
growth hormone responsive); cognitive deficits
(usually mild) and ADHD; lymphedema
DiGeorge syndrome 22q11.2 del
(most commonly)
1 in 4000 births IAA, CAT, TOF Cardiac defects (60–75%); short stature;





7q11.23 1 in 7500 births supraAS, supraPS Cardiac defects (75%); short stature; cognitive
deficits; hypercalcemia; social personality; type 2
diabetes mellitus
ADHD indicates attention deficit/hyperactivity disorder; ASD, atrial septal defect; BAV, bicuspid aortic valve; CAT, truncus arteriosus; CAVSD, complete atrioventricular septal defect; CoA,
coarctation of the aorta; dilated Ao, dilated ascending aorta; IAA, interrupted aortic arch; PDA, patent ductus arteriosus; supraAS and -PS, supravalvar aortic and pulmonary stenosis; TOF,
tetralogy of Fallot; and VSD, ventricular septal defect.
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commonly referred to as DiGeorge syndrome (DGS), although
not all patients with DGS have the 22q11.2 deletion and not
all individuals with the 22q11.2 deletion will display all the
features of DGS (summarized in Table 1). As with CHD
patients with larger chromosomal defects, growth, cognition,
and behavior are all significantly impacted by the underlying
genetic defect in patients with 22q11.2 deletions.
The presence of the 22q11.2 deletion also affects the
survival and complication rate of CHD repair. Patients with the
22q11.2 deletion and/or a diagnosis of DGS have worse
surgical outcomes, at least for certain types of CHD, including
pulmonary atresia with ventricular septal defect and inter-
rupted aortic arch.59,60 The worse surgical outcomes appear
to be in part due to more severe abnormalities of the
pulmonary vasculature, with an increased incidence of
multiple aortopulmonary collateral arteries and decreased
arborization of the true pulmonary arteries.61 For patients
with tetralogy of Fallot, those with 22q11.2 deletion
required longer cardiopulmonary bypass times and a longer
postoperative intensive care unit stay62 and had a worse
quality of life on long-term follow-up.63 Associated immune
defects require special handling of the blood products that
are often required during the operation and in the
perioperative setting, but severe complications such as
graft-versus-host disease and overwhelming cytomegalovirus
infection can be avoided by administering only CMV-
seronegative/irradiated blood products to patients with
22q11.2 deletion or DGS.64
Other major deletion/duplication syndromes. For most
genes and CNVs, deletions are more clinically impactful than
the corresponding duplication. In addition to the 22q11.2
microdeletion syndrome, other CNVs commonly associated
with cardiac defects include microdeletion syndromes
involving 7q11.23 (Williams-Beuren syndrome), 1p36, and
8p23.
Williams-Beuren syndrome (WBS) is a microdeletion syn-
drome affecting multiple genes on chromosome 7q11.23. It
occurs in 1 in 7500 to 1 in 10 000 births and accounts for
0.25% of CHD, most commonly supravalvar aortic or
pulmonary stenosis.40 WBS patients have growth deficiency
that begins in utero and persists through childhood.65
Cognitive and behavioral deficits are common,66 and multiple
organs and tissues can be affected (see Table 1).67 In
addition, patients with WBS, in particular those with biven-
tricular outflow tract obstruction and/or coronary ostial
stenosis, are at risk for sudden death, especially when
undergoing perioperative or periprocedural sedation, requiring
careful anesthetic management and monitoring.68,69 The risk
of death is also present in patients with elastin arteriopathy
(due to mutation or deletion of the elastin gene) in the
absence of other features of WBS.
Other microdeletions and microduplications are also
associated with CHD, and 2 additional CNVs occur often
enough to be addressed specifically. Microdeletions of 1p36
occurs in 1 in 5000 births and are associated with
abnormalities of cardiac structure (including patent ductus
arteriosus, and atrial and ventricular septal defects) and/or
function (specifically left ventricular noncompaction cardiomy-
opathy) in 70% of cases.70 Nearly all of those affected will
have short stature and significant ND delay. Microdeletions of
chromosome 8p23.1 are uncommon in the general population
but can be found in a significant number of patients with CHD
due to the loss of the GATA4 gene, a transcription factor
critical to heart development.71 In addition to cardiac defects,
dysmorphic facies, short stature, and developmental delay are
common features of 8p23.1 deletion syndrome.72
Rare and de novo CNVs. Pathogenic or potentially
pathogenic CNVs have been determined to occur in 10% to
20% of patients with CHD.20,34 While these commonly occur in
patients with recognizable syndromes (such as DGS or WBS)
and patients with dysmorphic features and/or multiple
congenital anomalies, even nonsyndromic, nondysmorphic
CHD patients are significantlymore likely to harbor a potentially
pathogenic CNV than individuals in the general population
without CHD. In a series of 422 patients with nonsyndromic,
isolated CHD (ie, no other anomalies), potentially pathogenic
CNVs occurred in 12.1% of cases compared with 5% of
healthy controls.34 Similarly, in a series of 223 patients with
single-ventricle cardiac defects, potentially pathogenic CNVs
occurred in 13.9% compared with 4.4% of healthy controls.20 In
a study of 2256 individual subjects with CHD, 283 parent-child
trios with CHD (tetralogy of Fallot) in the child, and 1538
controls, rare deletion CNVs (those occurring in <1% of the
population at large) affected more genes and genes with higher
haploinsufficiency scores (a measure of a gene’s developmen-
tal intolerance of gene deletions) in CHD patients than in
controls.73 Rare de novo CNVs occurred in 5% of the CHD trios,
and several overlapping CNVs involved genes known to be
involved in heart development including HAND2 and GJA5,
which encode for a cardiac transcription factor and gap junction
protein, respectively.73 In that study, theywere unable to detect
a significant association of rare duplications with CHD,
supporting the assertion that, in general, deletions more
commonly have an impact on cardiac development. Mapping of
overlapping, rare CNVs across multiple studies and identifying
common critical regions facilitates identification of novel genes
and signaling pathways involved in CHD pathogenesis.33,73,74
Given that pathogenic and potentially pathogenic CNVs
can involve multiple adjacent genes and include genes critical
to disease processes, it is perhaps not surprising that CNVs
have been associated with multiple adverse outcomes in
patients with CHD. As demonstrated for the CNVs associated
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with syndromic CHD, single-ventricle-type CHD patients with
pathogenic CNVs have worse linear growth and neurodevel-
opmental performance (as determined by a lower Psychomo-
tor Development Index score on the BSID-II) at 14 months of
age than those without CNVs.20 In a cohort of nonsyndromic
patients with a broad range of heart defects requiring surgery
before 6 months of age, presence of a potentially pathologic
CNV was associated with a 2.6-fold increased risk of death or
transplant by 36 months post-surgery.34 It is important to
note that this study excluded all subjects with other
significant congenital anomalies, indicating that the effect
on transplant-free survival was independent of any other
known developmental abnormalities. Since pathogenic CNVs
associated with CHD are distributed throughout the genome
and involve a diverse set of genes, it will be important to
identify the specific genes and signaling pathways associated
with differential outcomes to develop protective and thera-
peutic strategies and improve risk assessment.
Single gene syndromes
RASopathies. The RASopathies are a group of autosomal-
dominant disorders with overlapping cardiac, growth, facial,
and ND features caused by genes involved in the RAS
mitogen-activated protein kinase pathway. The spectrum of
RASopathies includes Noonan syndrome (NS), cardiofaciocu-
taneous syndrome, Costello syndrome, and NS with multiple
lentigines. Fifty percent of NS cases are explained by
heterozygous PTPN11 missense pathologic variants.75 An
additional 30% can be explained by mutations in one of the
RAS MAP kinase pathway genes including SOS1, RAF1, RIT1,
KRAS, SHOC2, NRAS, SOS2, BRAF, A2ML1, LZTR1, MYST4,
RASA2, RRAS, SPRY1, and SYNGAP1.76 NS and the other
RASopathies share common features, including developmen-
tal delays, short stature, ptosis, hypertelorism, macrocephaly,
and cardiac involvement (see Table 1).77–80 Valvar pulmonary
stenosis is a common form of CHD noted in patients with NS;
however, NS patients with pulmonary stenosis are often not
considered to be good candidates for balloon valvuloplasty
due to the high rates of required reintervention (65%) after
this procedure in the NS population.81
Coagulation factor deficiencies, thrombocytopenia, and
platelet aggregation abnormalities have been reported,82 but
are infrequently associated with postoperative bleeding
complications (<2% of individuals).83 Lymphatic abnormalities
are common, and chylous effusion is a regularly reported
complication of cardiac surgery. Renal anomalies including
vesicoureteral reflux, hydronephrosis, and dysplastic kidney
are seen in 10% to 20% of individuals.84
Ciliopathies. Ciliopathies are due to abnormal cilia structure
and function and are associated with heterotaxy and a range
of genetic syndromes including Bardet-Biedl syndrome,
Alstrom syndrome, McKusick-Kaufman syndrome, and Ellis
van Creveld syndrome. The associated clinical features vary
by condition.
Heterotaxy is associated with CHD in 50% to 95% of cases
and can be associated with almost any type of CHD, but the
most common defect is an atrioventricular canal defect that is
frequently unbalanced.85 Heterotaxy can be associated with
complete situs inversus, left atrial isomerism (polysplenia),
and right atrial isomerism (asplenia). Abnormalities of spleen
number (asplenia or polysplenia) may result in functional
asplenia with increased susceptibility to infection. Gut
malrotation poses a risk for volvulus. Extrahepatic biliary
atresia is a significant extracardiac complication that
increases mortality. As many as 37% of heterotaxy patients
may have primary ciliary dyskinesia, which is associated with
chronic productive cough, rhinitis, sinusitis, otitis media,
bronchitis, and bronchiectasis.86 Poor mucociliary clearance
leads to infection and inflammation of the airway and may
contribute to the higher frequency of respiratory complica-
tions in patients with ciliary dysfunction.87 Cognition and
intellectual function are usually normal.
Syndromic sensory ciliopathies are caused by abnormali-
ties in the sensory or signaling functions of cilia and are
commonly associated with defects in the eyes, ears, skeleton,
brain, kidney, and liver in addition to CHD that includes situs
abnormalities, atrioventricular canal defects, septal defects,
and valve defects.88–93 Common features include retinitis
pigmentosa, cone-rod dystrophy, sensorineural hearing loss,
and brain malformations including brain stem malformations
(molar tooth sign), Dandy-Walker malformation, neural tube
defects including encephalocele, holoprosencephaly, and
agenesis of the corpus callosum. Many individuals with
syndromic sensory ciliopathies are developmentally delayed
or intellectually disabled. Obesity and diabetes mellitus are
common. Skeletal anomalies can be associated with short
stature, thoracic dysplasia, short limbs, and polydactyly.
Hepatic fibrosis, hepatic cysts, polycystic kidneys, and
nephronophthisis are observed with many of the conditions.
Chromatin modifiers. Initial studies in families affected by
heritable congenital cardiac defects identified mutations in
cardiac transcription factors such as NKX2-5, GATA4, TBX5,
TBX1, and TBX20 as important causes of CHD. For some of
these transcription factors, the effects were limited to the
heart, which is where they are primarily expressed. Other
cardiac transcription factor mutations, such as those involving
TBX5 (associated with Holt-Oram syndrome) and TBX1
(associated with some features of DGS), have major extrac-
ardiac manifestations but are not associated with known
differences in clinical outcomes. Perhaps the most important
cardiac complication of transcription factor mutations is
disruption of the cardiac conduction system, which can lead
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to complete heart block in some individuals with NKX2-5 and
TBX5 mutations.94,95
However, regulators of the transcriptional machinery, such
as those that modify chromatin architecture by altering histone
structure and function through acetylation, methylation, phos-
phorylation, and ubiquitination, are often more broadly
expressed and, when mutated, can affect the development of
multiple organs and tissues in a manner that directly impacts
clinical outcomes. Mutations of the chromatin modifiers,
KMT2D and KDM6A, which encode for lysine (K)-specific
methyltransferase 2D and lysine-specific demethylase 6A,
cause Kabuki syndrome, a developmental disorder affecting
the heart, brain, urogenital system, craniofacial structures, and
linear growth (height). Heart defects, which can range from
mild (atrial septal defect, ventricular septal defect, patent
ductus arteriosus, coarctation of the aorta) to more severe
(tetralogy of Fallot, single-ventricle CHD), occur in 31% to 58%
of Kabuki syndrome patients.96,97 Observed cardiac defects
often involve left ventricular outflow tract obstruction, includ-
ing Shone complex and hypoplastic left heart syndrome
(HLHS). In a recent study performed by the Pediatric Cardio-
vascular Genomics Consortium (PCGC) of 362 cases of critical
congenital cardiac defects including 60 patients with HLHS, de
novo mutations were noted in 8 genes involved in the
regulation of methylation of histone H3, lysine 4 (H3K4),98
including KMT2D (associated with Kabuki syndrome); CHD7
(associated with CHARGE syndrome); KDM5A and KDM5B
(H3K4 demethylases); WDR5, and RNF20, UBE2B, and USP44,
which are involved in histone ubiquitination. Mutations were
also noted in SMAD2, which is involved in signaling in the
embryonic left-right organizer through demethylation of
H3K27. In this study, the patients with mutations involving
histone-modifying genes had a higher incidence of extracardiac
manifestations including developmental delay and short
stature.
Single gene (nonsyndrome)
De novo variants. Exome sequencing analysis of the PCGC
cohort has demonstrated that 10% of CHD can be explained
by de novo single-nucleotide variants. When the cohort is
parsed by associated abnormalities, de novo variants in genes
highly expressed in the heart contribute to 10% of CHD
associated with extracardiac anomalies, 6% of CHD with ND
abnormalities, and 20% of CHD associated with both extrac-
ardiac and ND abnormalities.32 These findings suggest a
pleiotropic effect of many of these de novo mutations.
The extracardiac abnormalities found in the PCGC cohort
are wide ranging and affect many different organ systems,
including craniofacial, pulmonary, gastrointestinal, orthopedic,
and genitourinary, among others. Patients with CHD and
extracardiac abnormalities are at increased risk of mortality
due to increased complexity of care, increased risk of cardiac
surgery, and additional sources of potential morbidity and
mortality.99,100
There was significant overlap between the genes with de
novo mutations found in the PCGC cohort and genes with de
novo mutations found in cohorts of patients ascertained for
neurodevelopmental phenotypes. These overlapping genes are
typically expressed in both the developing heart and brain.
CHD patients with damaging de novo mutations found in these
overlapping genes have an absolute risk of >70% of having ND
abnormalities.32 Of the groups of genes identified, damaging
mutations in the chromatin modifier genes had the highest risk
of conferring a ND abnormality phenotype. These findings are
significant because they provide a causal genetic link between
CHD and ND abnormalities and imply that specific genotypes
may strongly predict future ND outcome. They also have
potential clinical implications. It is possible to imagine a clinical
genetic test that can identify patients at particularly high risk of
poor ND outcomes to target for neuroprotective measures and
early childhood surveillance and intervention.
Structural proteins. While more commonly associated with
cardiomyopathy (dilated, hypertrophic, or restrictive), muta-
tions in genes encoding for components of the cardiac
sarcomere, the basic contractile unit of striated muscle, have
been determined to be responsible for familial and sporadic
CHD. Examples include mutations in MYH7 (b myosin heavy
chain) in individuals with Ebstein anomaly of the tricuspid
valve, in ACTC1 (cardiac a actin) in familial ASD, and in MYH6
(a myosin heavy chain 6) in autosomal dominant familial ASD
and sporadic cases of more complex CHD, including Shone
complex and HLHS.35 There is mounting evidence that genetic
variation in sarcomeric genes can concurrently cause CHD
and affect ventricular function. Mutations in MYH7 that cause
Ebstein anomaly also lead to ventricular noncompaction and
reduced ventricular function.101 Similarly, multiple studies
have shown that CHD patients with sarcomeric mutations
have differential clinical outcomes, including reduced ventric-
ular performance and transplant-free survival. In a recent
study of 2645 parent-offspring trios and 226 singletons who
underwent exome sequencing by the PCGC, 7 had recessive
genotypes involving MYH6.35 Five of the 7 had left ventricular
outflow tract obstructive lesions, including 4 with Shone
complex (which is characterized by mitral and aortic valve
abnormalities). Abnormal ventricular function was noted in 4
of the 7 subjects with MYH6 mutations. Reduced ejection
fraction, a measure of systolic ventricular function, was also
noted in 2 subjects with HLHS who had recessive MYH6
mutations.102 A case-control study of 190 patients with HLHS
noted an increased burden of damaging MYH6 variants in
HLHS cases versus 1000 Genomes Project controls and
reduced transplant-free survival in HLHS patients with MYH6
mutations compared with other HLHS patients.103 The
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differential survival was potentially due to impaired car-
diomyogenesis and to dysregulation of genes related to
myocardial structure and function. Collectively, these studies
demonstrate the increasingly recognized role of sarcomeric
genes in the pathogenesis of CHD and the important effect
that sarcomere gene mutations have on ventricular function
and long-term survival.
Genetic Modifiers of Clinical Outcomes
In addition to rare and de novo DNA sequence variants that
can affect developmental pathways directing morphogenesis
of the heart and other organs and tissues, more common
genetic variants (which may not have any clinical effect under
normal conditions) may lead to important differences in
treatment responses and be important modifiers of clinical
outcomes. Multiple clinical outcomes in patients with CHD,
including survival, ND performance, and ventricular remodel-
ing and function, have been demonstrated to be in part
dependent on common genetic variants.
Perhaps the best described of these common genetic
variants involves the ND effects of the different alleles of
apolipoprotein E (ApoE) in patients with CHD. ApoE is a
lipoprotein that is a primary cholesterol transporter in the
central nervous system.104 It is produced by astrocytes and
transports cholesterol to surrounding neurons. Its fundamen-
tal role in a wide range of neurologic conditions has been well
described,105–107 and it appears to be an important regulator
of neuronal homeostasis and resistance to injury. There are
multiple isotypes of ApoE (e2, e3, e4) with different functional
properties. Individuals with at least 1 copy of the e4 allele are
at higher risk of Alzheimer disease108 and worse outcomes
after traumatic brain injury.109 In patients with CHD, the ApoE
e2 allele is associated with worse early ND performance in
patients with CHD,110 a deficit that persists as patients age111
and that has been replicated in a similar but distinct patient
cohort.112 It has been proposed that ApoE allele status affects
neuroresiliency and that the ApoE e2 allele renders patients
less resistant to neuroinjury that may occur in utero or
perioperatively in patients with CHD.
Ventricular remodeling and function and postoperative
survival in CHD has also been determined to be in part
dependent on common genetic variants. Genetic variants
associated with increased activation of the renin-angioten-
sin-aldosterone system were determined to be associated
with multiple outcomes, including the reverse remodeling
that occurs after the second-stage palliative surgery for
patients with single-ventricle CHD113 and is associated with
impaired diastolic function after the third stage of repair for
single-ventricle CHD, the Fontan operation.114 A vascular
endothelial growth factor A allele linked to enhanced
vascular endothelial growth factor A expression was associated
with preserved ventricular function115 and postoperative
survival116 in patients requiring CHD surgery in infancy. Lower
event-free survival has also been associated with adrenergic
signaling pathway variants that increase catecholamine release
or sensitivity in patients with single-ventricle CHD.117
Implications for Clinical Care/Outcomes
Improvement/Future Research
Perioperative Management
With an increased understanding of how genetic factors affect
clinical outcomes (summarized in Table 2), there will be
opportunities to target therapies to the specific needs of each
individual patient. Currently, the most important role for
preoperative genetic testing is in the CHD patient with possible
22q11.2 deletion syndrome. As noted above, patients with
22q11.2 deletion syndrome have thymic hypoplasia, which
requires special handling of blood products before transfusion
or exposure during cardiopulmonary bypass. Since clinical
features of 22q11.2 deletion syndrome may not be apparent,
especially in infants, testing for 22q11.2 deletion should be
performed by fluorescent in situ hybridization, multiplex
ligation-dependent probe amplification assay, or quantitative
polymerase chain reaction. Alternatively, chromosomal
microarray testing can detect microdeletions and duplications
anywhere throughout the genome. In addition to special
handling of blood products, serum calcium levels need to be
closely monitored and repleted as needed. The differential
outcomes in subjects with 22q11.2 deletion and pulmonary
atresia/ventricular septal defect may be primarily related to
differences in vascular anatomy and may not require additional
considerations for the genetic etiology beyond that required to
address the more complex anatomy. Similarly, specific
anatomic features such as coronary ostial abnormalities and
biventricular outflow obstruction place patients with elastin
arteriopathy (including those with WBS) at risk for sudden
death, requiring cautious anesthetic management.
Another scenario in which differential clinical outcomes
requires careful consideration of surgical approach and treat-
ment plan involves the trisomy syndromes, including trisomy
13, 18, and 21. As noted above, low survival rates for patients
with trisomy 21 and single-ventricle cardiac defects (or trisomy
13 or 18 and any cardiac defect) has led many institutions to
advise against palliative intervention in those cases.
Future improvements in perioperative and longitudinal care
practices may rely in part on an improved understanding of
individual factors, both genetic and nongenetic (ie, related to
patient age, sex, medical history, and other health and
treatment factors), that affect treatment response and clinical
outcomes. Some of these will be related to pharmacogenomic
factors, which affect a patient’s biologic response to specific
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drugs. The studies examining the effects of renin-angiotensin-
aldosterone system pathway genetic variation (and targeting
of that pathway with angiotensin-converting enzyme inhibi-
tion)113,114 as well those studies assessing the effect of
adrenergic pathway variation on clinical outcomes117 in
patients with CHD indicate that therapeutic approaches
tailored to specific genetic profiles may help improve
outcomes. This type of precision medicine approach has
been applied in other medical settings and is just beginning to
be considered for the care of patients with CHD.
Outcomes Assessment/Improvement
Perhaps the most immediate implication of the improved
understanding of the impact of genetic factors on clinical
outcome measures in patients with CHD is the need to account
for those factors in outcomes research and analyses. As noted
above, genetic factors can affect multiple outcomes measures
(including neurodevelopment, growth, ventricular function, and
survival), with effects that range from rare to common in
prevalence and from mild to substantial in severity. While
randomization may be able to distribute genetic factors
between treatment groups in large trials, failure to account
for important genetic determinants to specific outcomes
measures may mask or dilute important treatment effects if
the genetic effect is an unmeasured confounder of the
treatment. As genetic determinants of CHD outcomes become
better defined, it may be possible to stratify subjects by genetic
risk for specific outcomes to identify different subpopulations
responsive or resistant to the treatment or intervention.
ND performance
Cognition and higher-level processing, motor function, and
behavior and attention can all be significantly affected by
Table 2. Impact of Major Categories of Genetic Determinants of CHD and Their Effects on Selected Clinical Outcomes
Type of Genetic Variation
Outcome Domain
Survival ND Growth V Function Notes
Chromosomal abnormality
Down syndrome +/* ++ +++  Higher mortality for single V heart defects;
other defects unaffected*
Trisomy 18 ++ ++++ ++++ 
Trisomy 13 +++ ++++ ++++ 
Turner syndrome   +++ 
CNV
22q11.2 +/* + ++  Higher mortality for pulmonary atresia with
VSD; other defects unaffected*
Williams syndrome + + ++ 
1p36 del + + + 
Others + + + 
Single gene disorders (rare variant)
RASopathies +/*  to ++ +  Higher mortality in cases with severe, early HCM*
Ciliary defects     Increased respiratory complications
Transcription factor    
Chromatin remodeling  + + 
Sarcomeric    ++
Single gene disorders (common variant)
ApoE (e2 allele)  +  
RAAS pathway    +* Effect on ventricular remodeling in
single V heart disease*
VEGFA variant +   +
Adrenergic signal +   
Magnitude of effect represented by the number of +. No known effect represented by . Outcomes include survival, neurodevelopment (ND), growth and ventricular (V) function. ApoE
indicates apolipoprotein E; CNV, copy number variant; HCM, hypertrophic cardiomyopathy; RAAS, renin-angiotensin-aldosterone system; single V, single-ventricle; VSD, ventricular septal
defect; and VEGFA, vascular endothelial growth factor A.
*indicates that there is a explanation of the score in the notes for that outcome.
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genetic factors in patients with CHD. Therefore, studies
assessing for the effectiveness of therapeutic interventions on
ND outcomes in patients with CHD should ideally be
structured to account for important genetic determinants in
the analysis. It will be important to determine if specific types
of genetic differences are equally distributed between the
treatment groups and between treatment responders and
nonresponders. It may be that the effectiveness of specific
interventions designed to promote neurodevelopment may be
less effective in those subjects with certain genetic features,
and their inclusion in a batch analysis may obscure the
effectiveness of the intervention in other patients.
Work to date suggests that just eliminating from the
analysis those subjects with recognizable syndromes may not
be sufficient to account for significant genetic effects on ND
performance measures. Genomic characterization (chromo-
somal microarray analysis) and exome/genome sequencing of
nonsyndromic CHD subjects has determined that pathogenic
CNVs and mutations in genes responsible for both heart and
brain development occur with sufficient frequency and have a
significant enough impact to merit consideration when
assessing ND performance in patients with CHD. Recent
trials have sought to better understand ND deficits using
anatomic and functional neuroimaging and to improve ND
outcomes using early intervention strategies. Including in
these studies patients who have undergone detailed genomic
characterization will improve our understanding of how
genetic factors influence brain structure and organization
and affect ND performance and the response to intervention.
We anticipate, based on the work to date, that genetically
determined deficits will affect different ND domains and will
be best accommodated by ND domainspecific and/or
genetic mechanism-specific interventions. Similarly, the effec-
tiveness of any ND intervention will be best assessed with
respect to any underlying genetic susceptibility.
Growth
As noted above, catch-up weight gain is more achievable than
maintenance of normal length.17–19 As a result, practices
aimed at improving neonatal and infant growth may be
responsible for the increased incidence of abnormal body
mass index now reported in adolescents with CHD. While
disease-specific growth curves are available, and commonly
used in clinical practice for some genetic syndromes (such as
trisomy 21), the adjustment for growth potential based on
less common genetic variations is not readily available. While
many clinicians may base caloric strategies on proportional
growth, better understanding of the genetic impact on growth
potential will allow for a more personalized approach in many
high-risk infants whose caloric intake is not self-regulated.
Furthermore, similar to the need to control genetic risk in ND
studies, research aimed at improving growth and minimizing
associated comorbidities may currently be confounded by the
inability to appropriately stratify treatment arms based on
their true growth potential.
Ventricular function
The impact of genetic variation on ventricular function in
patients with CHD is not yet well understood. Clearly, there are
common genetic variants (eg, vascular endothelial growth
factor A rs833069) that can have a modest impact on
ventricular function115,117 and rare genetic variants (eg,
selected MYH6 variants) that can have a more significant
impact.102 There are potentially 2 important implications of the
findings to date. First, it is important to note that there are an
increasing number of examples in which patients with CHD
have a mutation that affects a gene that can also cause
ventricular dysfunction and dilated cardiomyopathy. While this
may affect only a small percentage of patients with CHD, it may
be important to consider genetic testing for concurrent dilated
cardiomyopathy in a CHD patient with a decline in ventricular
function that is out of proportion to the cardiac lesion or
its treatment. Second, studies evaluating the impact of
common genetic variation on ventricular structure and
function113,114,117 suggest that variation in specific signaling
pathways such as the renin-angiotensin-aldosterone system or
adrenergic signaling may be suitable for pharmacologic target-
ing to help improve ventricular function, ventricular remodeling,
and even survival in all CHD patients or in selected patients with
genetic predisposition to over- or underactivation of those
pathways. Ongoing studies examining ventricular function (in
both a longitudinal and cross-sectional manner) in CHD
subjects who have had genomic characterization with exome
or genome sequencing will likely identify novel mediators of
ventricular function in CHD patients and help assess the
relative impact of genetic variation on clinical outcomes related
to ventricular performance.
Survival
Different mechanisms likely affect early peri-operative survival
compared with long-term survival. To date, genetic determi-
nants such as the presence of a pathogenic CNV or inherited
variants in specific signaling pathways primarily affect mid- and
long-term survival after surgery for CHD in infancy. As these
genetic determinants of long-term outcomes become validated
and better defined, it may be possible to adapt longitudinal
follow-up and institute compensatory pharmacotherapy to help
modify and improve outcomes, especially in those at highest
risk. Identification of the genetic determinants of early
outcomes has been more challenging likely because of the
large effects of technical surgical factors and patient-specific
complications. It is anticipated that early outcomes, like mid-
and late outcomes, will be modified by specific genetic factors,
the identification of which may depend on more precise
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determination of the vulnerable or fragile patient that requires
escalation of care to prevent morbidities and mortality.
Future directions
Increasingly robust documentation and tracking of short- and
long-term outcomes combined with more widespread clinical
and research-based genetic characterization of CHD patients
promises to lead to rapid advances in the application of
precision medicine approaches to the care of patients with
CHD. Linkage of information across different data sources,
including genetic, surgical, and perioperative, and longitudinal
follow-up data sets, will help identify genetic patterns leading
to adverse clinical outcomes and foster the development of
individualized care and follow-up programs tailored to the
genetic strengths and vulnerabilities of each patient. Chal-
lenges will include (1) the storage, processing, and analysis of
large amounts of data; (2) the adjudication of variants as
pathogenic, likely pathogenic, or unknown significance (along
with real-time updating of status based on accumulating
evidence); (3) the assignment of relative contributions of
specific genetic factors to each outcome; and (4) the
maintenance of privacy protections as information is shared
across platforms and continually updated.
Summary
Rapid advances in the identification of the genetic determi-
nants of the causes of CHD coupled with the linkage of
genetic testing and clinical outcomes data has allowed
substantial improvement in our understanding of how genetic
variation affects clinical outcomes in patients with CHD. What
is emerging is that clinical outcomes in patients with CHD are
dependent on a combination of disease-specific, treatment-
related, and individual patient-specific factors. Underlying
genetic variation has an increasingly recognized important
impact on outcome measures, including neurodevelopment,
growth, ventricular function, and survival. Our ability to
accurately assess outcomes in patients with CHD and to
design and evaluate intervention strategies will depend on a
continued increase in our understanding of the relative impact
of each outcome determinant, including genetic determinants.
In time, this will hopefully lead to a precision medicine type of
approach in which best clinical practices are modified to
optimally meet the needs of each individual patient, resulting
in improved care and better clinical outcomes.
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